Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report

Ítems similars

• Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
  per: Wich, Christina, et al.
  Publicat: (2010)
• Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
  per: Zopf Steffen, et al.
  Publicat: (2012-09-01)
• Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
  per: Zopf, Steffen, et al.
  Publicat: (2012)
• The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
  per: Di Fazio, Pietro, et al.
  Publicat: (2010)
• The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models
  per: DI FAZIO, PIETRO, et al.
  Publicat: (2013)